Diagnostic Impact of Dual-Time PET/CT with <sup>68</sup>Gallium-PSMA in Prostate Cancer and <sup>68</sup>Gallium-DOTATOC in Neuroendocrine Tumors
Background: The timing of imaging for <sup>68</sup>gallium (<sup>68</sup>Ga)-PSMA and <sup>68</sup>Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demon...
Main Authors: | Damiano Librizzi, Friederike Eilsberger, Stefan Ottenthaler, Ali Ebrahimifard, Markus Luster, Behrooz H. Yousefi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/4/1052 |
Similar Items
-
Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01) -
Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [<sup>68</sup>Ge]Ge/[<sup>68</sup>Ga]Ga Generators: Fractional Elution or Prepurification?
by: Flore Durieux, et al.
Published: (2023-11-01) -
<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans
by: Licia Uccelli, et al.
Published: (2021-09-01) -
[<sup>68</sup>Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [<sup>177</sup>Lu]DOTATOC PRRT: The “Theragnomics” Concept
by: Riccardo Laudicella, et al.
Published: (2022-02-01) -
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)